Evidence for Tesamorelin in HIV-Associated Lipodystrophy
Tesamorelin is FDA-approved and guideline-supported for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy who are on stable antiretroviral therapy, demonstrating significant reductions in visceral adipose tissue (15–24%), improvements in lipid profiles, and favorable effects on liver fat. 1
FDA-Approved Indication and Patient Selection
Tesamorelin (Egrifta/Egrifta SV) is specifically indicated for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, administered as 1.4 mg (or 2 mg depending on formulation) subcutaneously once daily into the abdomen. 1
The drug is NOT indicated for weight loss management (it has weight-neutral effects) and does not improve antiretroviral therapy compliance. 1
Critical contraindications include: active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy, and known hypersensitivity to tesamorelin. 1
Clinical Efficacy: Visceral Fat and Body Composition
In pooled Phase III trials of 806 HIV-infected patients, tesamorelin reduced visceral adipose tissue by 15.2–24% (mean -24 ± 41 cm²) compared to placebo at 26 weeks, with sustained reductions of -35 ± 50 cm² (-17.5%) maintained through 52 weeks in continuous users. 2, 3
A more recent high-quality randomized trial demonstrated median visceral fat reduction of -25 cm² (interquartile range: -93 to -2) versus +14 cm² with placebo at 12 months. 4
Tesamorelin preserves subcutaneous adipose tissue (no significant changes: -2 ± 32 cm² vs. +2 ± 29 cm² with placebo), specifically targeting visceral fat accumulation. 3
The drug significantly reduces trunk-to-appendicular fat ratio (-0.1 vs. 0.0 with placebo, p=0.03), improving body fat distribution. 4
Metabolic Benefits Beyond Fat Reduction
Lipid Profile Improvements
Tesamorelin produces triglyceride reductions of 37–50 mg/dL at 26–52 weeks, with Phase III trials showing mean decreases of -37 ± 139 mg/dL versus +6 mg/dL with placebo (treatment effect -12.3%). 5, 6, 2, 3
The total cholesterol-to-HDL ratio decreases by -0.18 to -0.31 compared to increases of +0.18 to +0.21 with placebo (treatment effect -7.2%). 2, 3
Patients with metabolic syndrome or elevated baseline triglycerides are the best treatment responders, showing more pronounced visceral fat and lipid improvements. 5, 7
Hepatic Fat and Liver Enzyme Effects
In a dedicated randomized trial, tesamorelin reduced liver fat by median -2.0% (lipid-to-water percentage) versus +0.9% with placebo (net treatment effect -2.9%, p=0.003) over 6 months. 8
Among patients with baseline elevated transaminases (ALT or AST >30 U/L), visceral fat responders (≥8% VAT reduction) experienced ALT reductions of -8.9 ± 22.6 U/L versus +1.4 U/L in nonresponders (p=0.004) and AST reductions of -3.8 ± 12.9 U/L versus +0.4 U/L (p=0.04). 9
These liver enzyme improvements persisted through 52 weeks even after drug discontinuation, despite partial visceral fat reaccumulation. 9
Skeletal Muscle Quality
- Tesamorelin increases muscle density by 1.56–4.86 Hounsfield units across four truncal muscle groups and increases lean muscle area by 0.64–1.08 cm² in all truncal groups (all p<0.005). 10
Glucose Monitoring Requirements and Safety
Glycemic Effects
Tesamorelin causes a transient early glucose elevation (mean +9 mg/dL at 2 weeks, treatment effect +7 mg/dL, p=0.03), but this effect stabilizes by 6 months with no significant differences in fasting glucose (treatment effect +2 mg/dL, p=0.72) or 2-hour glucose (treatment effect +7 mg/dL, p=0.53). 5, 8
Patients with pre-existing diabetes or glucose intolerance require particularly vigilant glucose monitoring during initiation, though no clinically meaningful changes in glucose parameters were observed in Phase III trials through 52 weeks. 5, 3
Even among patients on integrase inhibitors (associated with weight gain and metabolic dysfunction), tesamorelin showed no exacerbation of glycemic control while maintaining efficacy. 4
Monitoring Protocol
Fasting glucose and lipid panels should be monitored prior to and within 4–6 weeks after starting therapy, then regularly during treatment to assess metabolic improvements. 11, 5, 6
IGF-I levels increase by 81–108% with tesamorelin versus -5 to -7% with placebo, reflecting the drug's mechanism of action. 2, 3
Treatment Prioritization and Clinical Context
Management of advanced immunosuppression, opportunistic infections, malignancies, and HIV-associated wasting must take precedence over lipodystrophy treatment during initial HIV care. 5, 6
Wasting should be addressed before treating dyslipidemia or lipodystrophy. 5
Prior to tesamorelin's approval, no clearly effective therapy existed for HIV-associated fat accumulation; antiretroviral class switching or discontinuation yielded only minimal benefit in limited studies. 11, 5, 6, 7
HIV-associated lipodystrophy affects 25–75% of patients on antiretroviral therapy, with prevalence increasing with longer treatment duration. 11, 5, 6, 7
Efficacy with Modern Antiretroviral Regimens
- The most recent 2024 randomized trial specifically evaluated tesamorelin among patients on integrase inhibitor-based regimens (now the mainstay of HIV therapy), demonstrating maintained efficacy with significant visceral fat reduction (-25 cm²), hepatic fat reduction (-4.2%), and trunk-to-appendicular fat ratio improvement despite INSTIs' association with weight gain. 4
Long-Term Safety Considerations
Long-term cardiovascular safety has not been established. 1
Consider risk/benefit of continuation in patients who have not achieved visceral adipose tissue reduction, as the FDA label specifically notes this limitation. 1
Tesamorelin is generally well tolerated with adverse event rates similar to placebo in Phase III trials, though more patients withdrew due to adverse events in the tesamorelin group. 2, 3
Rotate injection sites to different areas of the abdomen to avoid injection site reactions; do not inject into scar tissue, bruises, or the navel. 1